UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 163

Sortiert nach

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

Annals of oncology, 2018-08, Vol.29 (8), p.1853-1860

2018

Volltextzugriff (PDF)

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome

Breast cancer research and treatment, 2018-09, Vol.171 (2), p.273-282

2018

Volltextzugriff (PDF)

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

The New England journal of medicine, 2022-05, Vol.386 (21), p.1973-1985

2022

Volltextzugriff (PDF)

LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816

Annals of oncology, 2022-09, Vol.33, p.S1415-S1416

2022

Volltextzugriff (PDF)

333P Evaluation of a composite PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant HER2-directed therapy in early breast cancer (TBCRC026)

Annals of oncology, 2023-10, Vol.34, p.S316-S316

2023

Volltextzugriff (PDF)

Abstract P4-10-06: Factors impacting the accuracy of self-reported breast procedures among women with and without breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-10-06

2019

Volltextzugriff (PDF)

191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)

Annals of oncology, 2022-09, Vol.33, p.S623-S624

2022

Volltextzugriff (PDF)

Abstract OT3-02-03: IMMUNe mOdulation in early stage estrogen receptor positive breast cancer treated with neoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT study (NCT03573648)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-02-03-OT3-02-03

2019

Volltextzugriff (PDF)

964MO Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844)

Annals of oncology, 2021-09, Vol.32, p.S833-S833

2021

Volltextzugriff (PDF)

239PTumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy

Annals of oncology, 2019-10, Vol.30, p.v79

2019

Volltextzugriff (PDF)

239P - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy

Annals of oncology, 2019-10, Vol.30, p.v79-v79

2019

Volltextzugriff (PDF)

Abstract P4-01-16: Detection of plasma tumor DNA (ptDNA) in patients with hormone receptor-positive HER2-negative (HR+HER2-) early breast cancer (EBC) in clinical remission

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-01-16

2019

Volltextzugriff (PDF)

Abstract P3-07-62: Association of overexpression of hypoxia inducible factor 1α with response to neoadjuvant chemotherapy in early stage breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-62

2016

Volltextzugriff (PDF)

Abstract P6-03-07: An automated DNA methylation assay (QM-MSP) for rapid breast cancer diagnosis in underdeveloped countries

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P6-P6-03-07

2018

Volltextzugriff (PDF)

Abstract P6-07-33: A clinicopathologic analysis of 45 patients with metaplastic breast cancer

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P6-P6-07-33

2012

Volltextzugriff (PDF)

Abstract PD6-08: IMAGE: Individualized molecular analyses guide efforts in breast cancer with comprehensive genomic profiling of tissue and plasma tumor DNA

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.PD6-08-PD6-08

2016

Volltextzugriff (PDF)

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas

Human pathology, 2016-01, Vol.47 (1), p.52-63

2016

Volltextzugriff (PDF)

Implications of the tumor immune microenvironment for staging and therapeutics

Modern pathology, 2018-02, Vol.31 (2), p.214-234

2018

Volltextzugriff (PDF)

GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas

Human pathology, 2013-07, Vol.44 (7), p.1341-1349

2013

Volltextzugriff (PDF)

The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice

The Journal of pathology, 2020-04, Vol.250 (5), p.667-684

2020

Volltextzugriff (PDF)

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Clinical cancer research, 2020-08, Vol.26 (16), p.4268-4279

2020

Volltextzugriff (PDF)

Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer

Frontiers in physiology, 2020-10, Vol.11, p.583333-583333

2020

Volltextzugriff (PDF)

1 – 25 von 163

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(153)
Mit Volltextzugriff
(152)

Publikationsform

Sprache

Englisch
(163)
Japanisch
(23)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816

333P Evaluation of a composite PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant HER2-directed therapy in early breast cancer (TBCRC026)

Abstract P4-10-06: Factors impacting the accuracy of self-reported breast procedures among women with and without breast cancer

191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)

Abstract OT3-02-03: IMMUNe mOdulation in early stage estrogen receptor positive breast cancer treated with neoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT study (NCT03573648)

964MO Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844)

239PTumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy

Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy

239P - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy

Abstract P4-01-16: Detection of plasma tumor DNA (ptDNA) in patients with hormone receptor-positive HER2-negative (HR+HER2-) early breast cancer (EBC) in clinical remission

Abstract P3-07-62: Association of overexpression of hypoxia inducible factor 1α with response to neoadjuvant chemotherapy in early stage breast cancer

Abstract P6-03-07: An automated DNA methylation assay (QM-MSP) for rapid breast cancer diagnosis in underdeveloped countries

Abstract P6-07-33: A clinicopathologic analysis of 45 patients with metaplastic breast cancer

Abstract PD6-08: IMAGE: Individualized molecular analyses guide efforts in breast cancer with comprehensive genomic profiling of tissue and plasma tumor DNA

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas

Implications of the tumor immune microenvironment for staging and therapeutics

GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas

The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer

Suchergebnisse filtern